Lower Dose is a Better Treatment Regimen for Lymph Cancer

A group of surveyors at the University Hospital of Cologne in Germany has revealed after its recent research, published in The Lancet, that lower dose of chemotherapy can be helpful in treating advanced stage Hodgkin's lymphoma in a much effective manner.

The team had conducted a study in order to test the different effects of different doses of a chemotherapy drug combination called BEACOPP. For the same, it enrolled nearly 2,000 people with the disease, the report says.

Advanced Hodgkin's lymphoma is a type of cancer that largely affects lymph tissue of patients, told the researchers. It has been found that around 1,700 people in the UK suffer from the same every year.

Concerning the situation, the study was conducted and participants were divided into three groups. Amongst the three, first group was given the standard treatment of eight cycles of chemotherapy with radiotherapy (group one) at an interval of three weeks.

The other group, as per the findings, was provided with six cycles of standard chemo plus radiotherapy (group two). While a third group received eight cycles of lower dose chemo drugs plus radiotherapy (group three). It has been told that the third group received the drugs every two weeks.

Along with it, imaging technique called a PET was also used by the researchers, which spotted patients at chances of being benefitted. The PET scans help in determining whether or not there is a need for a further radiotherapy after chemotherapy.

It was then concluded by them that Five-year Freedom from Treatment Failure (FFTF) was worst in group. Nonetheless, survival rate was the greatest in the third group and slightly less but sufficiently helpful for the second group. "Such a treatment could be less disruptive to people's lives”, said Debbie Coats, clinical information manager at Cancer Research UK.